An experimental pill may offer a different way to treat both type 2 diabetes and obesity other than a GLP-1.
Early studies suggest it can improve blood sugar control and encourage fat burning without some of the drawbacks commonly associated with current weight-loss medications.
Researchers behind the study say the treatment could help patients lose weight while preserving muscle mass, an important factor for long-term health and healthy aging.
The findings were published in the journal Cell by scientists from Karolinska Institutet and Stockholm University.
How This Drug Differs From Ozempic
Many of today’s best-known weight-loss treatments, including Ozempic and similar GLP-1 medications, work by reducing appetite and helping people eat less. They do not work by revving up the metabolism.
The new drug takes a completely different approach.
Rather than targeting hunger signals between the gut and brain, it focuses on metabolism inside skeletal muscle tissue.
Researchers say this strategy helps the body use energy more efficiently while improving blood sugar regulation.
In animal studies, the treatment improved body composition and metabolic health without triggering appetite suppression.
Scientists also reported fewer concerns related to muscle loss and digestive side effects, which can sometimes occur with GLP-1 therapies.
Unlike most GLP-1 medications, which require injections, the new treatment is taken orally as a pill.
Researchers believe this could make the therapy more appealing for patients who prefer not to use injectable medications.
Early Human Trial Results
The research team has already completed an initial Phase I clinical trial.
The study included 48 healthy volunteers and 25 participants living with type 2 diabetes.
According to the researchers, the treatment was generally well tolerated by participants.
While Phase I studies are primarily designed to evaluate safety rather than effectiveness, the results were encouraging enough to support further development.
One of the most notable aspects of the treatment is its focus on muscle health.
Muscle is the body’s metabolic furnace. It’s extremely important to maintain muscle mass throughout life. Loss of muscle = slower metabolism.
Researchers say preserving muscle while reducing excess body fat could provide meaningful advantages compared to treatments that lead to significant muscle loss alongside weight reduction.
The Science Behind the Drug
The medication is based on a specially designed molecule known as a beta-2 agonist.
Scientists engineered the compound to activate metabolic pathways in skeletal muscle while minimizing stimulation of the heart.
Historically, excessive cardiovascular effects have limited the usefulness of many beta-2 agonist drugs. Researchers believe they may have found a way to overcome that challenge.
The result is a compound intended to boost muscle metabolism without causing unwanted heart-related side effects.
What Happens Next
Although the early findings are promising, the treatment is still in the experimental stage.
The next major step will be a larger Phase II clinical trial designed to evaluate how well the drug performs in people with type 2 diabetes and obesity.
The study will be conducted by Atrogi AB, the company developing the therapy.
Researchers hope the upcoming trial will confirm whether the metabolic benefits observed in laboratory and early human studies can translate into meaningful improvements for patients.
If successful, the drug could represent a new category of treatment that helps improve blood sugar control, promote healthy weight loss, and preserve muscle mass — all without injections.
